• Explore /
  • Poster
  • / Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.

Potentially curative combination of TGF-b1 inhibitor losartan and FOLFIRINOX (FFX) for locally advanced pancreatic cancer (LAPC): R0 resection rates and preliminary survival data from a prospective phase II study.

Abstract Poster

Authors

null

Janet E. Murphy

Massachusetts General Hospital, Boston, MA

Janet E. Murphy , Jennifer Yon-Li Wo , David P. Ryan , Wenqing Jiang , Beow Y Yeap , Gabriel Dan Duda , Jill N. Allen , Lawrence Scott Blaszkowsky , Cristina Ferrone , Aparna Raj Parikh , Ryan David Nipp , Andrew X. Zhu , Lipika Goyal , Keith D Lillemoe , Thomas F. DeLaney , Rakesh K. Jain , Jeffrey W. Clark , Yves Boucher , Carlos Fernandez-del Castillo , Theodore S. Hong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01821729

Citation

J Clin Oncol 36, 2018 (suppl; abstr 4116)

DOI

10.1200/JCO.2018.36.15_suppl.4116

Abstract #

4116

Poster Bd #

305

Abstract Disclosures

Similar Posters

First Author: Janet E. Murphy

First Author: Janet E. Murphy

First Author: Jon Kroll Bjerregaard

First Author: Janet E. Murphy